Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Advances in Strategies Against Measles Spread: Clinical and Epidemiological Aspects, Impact, Vaccine Innovations, and Sustainable Recommendations.

TheScientificWorldJournal·2026
Same author

Moving beyond the empty cell: The threat of decontextualized healthcare data.

PLOS digital health·2026
Same author

Innovative Nanotechnology-Based Approaches for Treating Car Wash Wastewater With Low-Cost Composite Materials: A Review.

Water environment research : a research publication of the Water Environment Federation·2025
Same author

SUSTAINED COGNITIVE DECLINE IN MULTIPLE SCLEROSIS: INVESTIGATING THE ROLE OF WHITE MATTER LESION LOAD USING AN AI-DRIVEN BRAIN IMAGING APPROACH.

Psychiatria Danubina·2025
Same author

Bio-inspired computing and Machine learning analytics for future-oriented mental well-being.

SLAS technology·2025
Same author

Bio-inspired computing and Machine learning analytics for a future-oriented mental well-being.

SLAS technology·2025

Related Experiment Video

Updated: May 14, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Decoding Parkinson's progression: A multi-modal SuStaIn ensemble approach validated on real-world PPMI data.

Moad Hani1, Saïd Mahmoudi1, Mohammed Benjelloun1

  • 1Computer and Management Engineering Department, Faculty of Engineering, University of Mons, 7000 Mons, Belgium.

Neurobiology of Disease
|May 12, 2026
PubMed
Summary

This study compared Subtype and Stage Inference (SuStaIn) algorithm variants for Parkinson's disease (PD) progression modeling. An ensemble approach using SuStaIn subtypes improved prediction accuracy and identified a diffuse-malignant subtype for clinical trial enrichment.

Keywords:
Biomarker analysisDisease progression modelingMachine learningPPMI cohortParkinson’s diseasePatient stratificationPrognostic validationSuStaIn algorithm

More Related Videos

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Related Experiment Videos

Last Updated: May 14, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Area of Science:

  • Computational biology and bioinformatics
  • Neuroscience and neurology
  • Biostatistics and data science

Background:

  • Parkinson's disease (PD) presents significant heterogeneity in clinical symptoms and progression, challenging accurate prognosis and personalized treatment strategies.
  • Existing Subtype and Stage Inference (SuStaIn) algorithms offer probabilistic modeling but require extensive comparative analysis and real-world validation for PD.

Purpose of the Study:

  • To systematically compare various SuStaIn algorithm variants for modeling Parkinson's disease progression.
  • To validate the stability and prognostic capabilities of these SuStaIn variants using simulated data and real-world Parkinson's Progression Markers Initiative (PPMI) cohorts.

Main Methods:

  • A simulated PD cohort (n=400) with 12 motor/non-motor biomarkers and three predefined subtypes was created to mimic realistic data complexities.
  • Six SuStaIn variants (Z-score, Ordinal, Event-based Mixture, Missing Data, s-SuStaIn, Temporal SuStaIn) were benchmarked on simulated and PPMI data (N=624).
  • Model performance was assessed using cross-sectional subtype structure, test-retest stability (Cohen's κ), and prognostic prediction of clinical outcomes via Cox models.

Main Results:

  • Simulation revealed six interpretable biomarker domains and three subtypes (slow, intermediate, fast); Temporal and s-SuStaIn variants showed optimal performance.
  • PPMI data analysis identified three consistent subtypes: benign motor-predominant, intermediate mixed, and diffuse-malignant (PIGD-dominant).
  • Ensemble SuStaIn subtypes significantly improved motor progression (Δc=+0.067) and cognitive decline prediction (Δc=+0.136), with enhanced stability (κ=0.81).

Conclusions:

  • SuStaIn variants effectively capture distinct Parkinson's disease progression patterns, with an ensemble strategy providing stable and prognostically valuable subtypes.
  • The identified diffuse-malignant subtype can aid clinical trial enrichment, potentially reducing sample size by 63%.
  • This study provides a validated framework for applying algorithmic subtype discovery to real-world PD data, advancing precision medicine initiatives.